Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933836 · ClinicalTrials.gov registry record
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
A clinical trial of Open Angle Glaucoma (OAG), sponsored by Barnet Dulaney Perkins Eye Centers.
- Recruiting
- Registry status
- 55
- Enrollment target
- 1
- Study location
NCT06933836: Recruiting study of Open Angle Glaucoma (OAG), sponsored by Barnet Dulaney Perkins Eye Centers.
NCT06933836 is a study of Open Angle Glaucoma (OAG) that is actively recruiting participants, run by Barnet Dulaney Perkins Eye Centers. The registered enrollment target is 55 participants, roughly in line with the 57-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06933836, a study of Open Angle Glaucoma (OAG), is actively recruiting participants, sponsored by Barnet Dulaney Perkins Eye Centers.
- RECRUITING
- Registry status
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
Primary Outcome
Proportion of patients (%) with DSLT success as defined as IOP lowering of \>20% and no additional medications or procedures at 12 months.
Conditions Studied
Interventions
- DEVICE DSLT enables newly diagnosed patients to remain well controlled and off medications
Study Locations (1)
Arizona
- Barnet Dulaney Perkins Eye Centers - Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2027-12-31 |
What NCT06933836 shows while recruiting
NCT06933836 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 57-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target.
The record links to 1 condition, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which DSLT enables newly diagnosed patients to remain well controlled and off medications is the first listed.
NCT06933836 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06933836 about?
NCT06933836 is a clinical study titled "DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma". DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
What is the current status of trial NCT06933836?
This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2025-03-31. Estimated completion is 2027-12-31.
What conditions does trial NCT06933836 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG).
What interventions are being tested in trial NCT06933836?
The interventions under investigation include: DSLT enables newly diagnosed patients to remain well controlled and off medications (DEVICE).
Who is sponsoring clinical trial NCT06933836?
This trial is sponsored by Barnet Dulaney Perkins Eye Centers, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933836 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
RECRUITING · Phase 1
-
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI